Compare Pfizer Inc (PFE) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Wix.Com Ltd — how do they compare? Pfizer Inc trades at $27.78 (market cap $159.59B), while Wix.Com Ltd trades at $74.59 (market cap $3.05B). The key difference: Pfizer Inc is far larger — about 52.3× Wix.Com Ltd's market cap, and Pfizer Inc pays a 6.14% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Wix.Com Ltd for 62 Days on average.
| PFE | WIX | |
|---|---|---|
Market Cap | $159.59B | $3.05B |
Volume | 30,937,010 | 748,691 |
Sector | Health | Technology |
52-Week High | $29.02 | $145.54 |
52-Week Low | $23.67 | $40.43 |
Typical Hold Time | 158 Days | 62 Days |
Enterprise Value | $211.09B | $4.13B |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Wix.com trades at $74.13, showing modest daily gains of 0.3%. The stock faces technical headwinds with a bearish moving average signal and RSI near overbought levels at 72.1. Fundamentally, revenue growth continues with 2025 reaching $1.99B, though profitability remains inconsistent with a negative net income margin of -8.19% in 2026. Analyst sentiment remains positive with 63% buy ratings and a $77 consensus target, but multiple class action lawsuits filed in September 2026 create near-term uncertainty.
Wix presents a mixed investment case with strong revenue growth offset by profitability challenges. The 3.9% upside to consensus target suggests modest near-term potential, but legal overhangs and volatile earnings create significant risk. Investors should weigh the company's market position against execution risks and legal uncertainties before establishing positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
